COVID-19 mRNA Vaccine Development

Call for wearing a protection face mask against coronavirus.

Creative Biogene is a leading service provider in the field of mRNA technologies, providing solutions to meet the need of worldwide customers in mRNA-based drug research and development, especially in mRNA vaccine development against infectious diseases. In the past years, coronavirus disease 2019 (COVID-19), a pandemic induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), poses extreme health threats as well as tremendous economic loss worldwide. Here, we are dedicated to performing research and proud to provide solutions for the development of mRNA vaccines against SARS-CoV-2, ranging from vaccine antigen design, mRNA vaccine manufacturing as well as mRNA vaccine characterization.

About COVID-19 mRNA vaccine

COVID-19 is an emerging disease, caused by SARS-CoV-2 infection. This virus can cause severe and fatal complications, especially for high-risk groups. Since the outbreak of COVID-19, the whole world is facing a tremendous test of all time, socially and economically, not to mention many people's well-being. Researchers have been focused on the novel and effective mRNA vaccine. mRNA vaccine is a new type of vaccine. Being different from conventional vaccines which rely on weakened or inactivated viruses to induce an immune response in a body, mRNA vaccines make the cells produce the desired protein, then trigger an immune response. mRNA vaccine holds the potential for the pandemic threat due to its fast, large-scale, flexible and cost-effective production based on a universal R&D and production platform. At present, the ongoing mRNA vaccine studies have been aiming mostly at the spike protein (S) and the virus-like particles (VLPs) of SARS-CoV-2.

COVID-19 mRNA vaccine development in Creative Biogene

SARS-CoV-2 are spherical viruses with protrusions on their surfaces. The viral genome is positive-sense, single-stranded RNA with a diameter of 75-160nm. The virus genome encodes spike protein (S), envelope protein (E), membrane protein (M) as well as nucleoprotein (N). Among them, S protein is a very important surface protein of coronavirus, which is closely related to the transmission ability of the virus. And the S, E, and M proteins together create the viral envelope. While N protein holds the RNA genome and is abundant in coronavirus, as a highly immunogenic protein, N protein is involved in genome replication and cell signaling pathway regulation, and is often used in the diagnosis of coronavirus.

Based on the in-depth knowledge of coronavirus and advanced mRNA technologies, we have the capability to produce mRNA vaccines with a rapid and robust immunogenicity profile, which enables efficient within-host antigen production and promotes antibody responses to SARS-CoV-2. According to the key targets of SARS-CoV-2, we conduct vaccine antigen design and mRNA synthesis in a targeted and scalable manner. Our modular platform can help standardize vaccine studies and allow rapid and flexible design and production of mRNA vaccines for specific and directed immune responses. The main modules include,

  • Antigen sequence design and optimization
  • mRNA synthesis and optimization
  • A potent delivery system
  • Vaccine safety and efficacy evaluations

Advantages of our solution

  • Fast and scalable response platform
  • Professional technical support
  • One-stop solutions
  • Most competitive prices

Creative Biogene is proud to be among the teams working to cope with the novel coronavirus. We strive to promote mRNA vaccine against infectious diseases into clinical trials. If you have any needs for mRNA vaccine development, please don't hesitate to contact us for more details.


  1. Xu, S., et al. (2020). "mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection." International Journal of Molecular Sciences, 21(18), 6582.
For research use only. Not intended for any clinical use.
Offer for you
Online inquiry
Copyright © 2024 Creative Biogene. All rights reserved.